Roche details Tamiflu production capacity

Share this article:
Roche said its current production network was on track to produce 300 million treatments of Tamiflu annually by 2007 and negotiations with third parties to produce the drug have begun.
Roche said in a statement today that it had received more than 150 requests from third parties to produce Tamiflu and it was in early talks with eight companies, amongst them large generic manufacturers, pharmaceutical firms and governments.
"Patients' needs in case of a pandemic remain our top priority. William Burns, CEO of Roche's pharma division, said in a statement. "We have continually increased our production capacities and are now putting in place the means to increase production of Tamiflu to 300 million treatments as of 2007. In addition, we have entered into discussions with a number of interested parties to expand world wide supply, so governments can be as prepared as possible for when the influenza pandemic happens."
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union